Synergy Pharmaceuticals Inc  

(Public, NASDAQ:SGYP)   Watch this stock  
Find more results for SGYP
8.68
-0.27 (-3.02%)
After Hours: 8.65 -0.03 (-0.35%)
Aug 4, 7:26PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.64 - 8.95
52 week 2.45 - 10.15
Open 8.91
Vol / Avg. 3.00M/5.89M
Mkt cap 895.41M
P/E     -
Div/yield     -
EPS -1.12
Shares 100.05M
Beta 0.49
Inst. own 31%
Aug 13, 2015
Synergy Pharmaceuticals Inc at Canaccord Genuity Growth Conference - 11:30AM EDT - Add to calendar
Jul 8, 2015
Synergy Pharmaceuticals Inc at Cantor Fitzgerald Inaugural Healthcare Conference
May 11, 2015
Q1 2015 Synergy Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -53.83% -66.95%
Return on average equity - -381.39%
Employees 35 -
CDP Score - -

Address

420 Lexington Ave Rm 2012
NEW YORK, NY 10170-2099
United States - Map
+1-212-2970010 (Phone)
+1-212-2970019 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company's platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Company's products include plecanatide, SP-333 and FV-100. The Company's lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Company's subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Officers and directors

Gary S. Jacob Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 68
Bio & Compensation  - Reuters
Patrick H. Griffin M.D. Executive Vice President and Chief medical officer
Age: 60
Bio & Compensation  - Reuters
Bernard F. Denoyer CPA Senior Vice President - Finance, Secretary, IR Contact Officer
Age: 67
Bio & Compensation  - Reuters
Kunwar Shailubhai Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Troy Hamilton Chief Commercial Officer
Bio & Compensation  - Reuters
Thomas H. Adams Jr., Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 67
Bio & Compensation  - Reuters
Timothy Callahan Independent Director
Bio & Compensation  - Reuters
Richard J. Daly Independent Director
Age: 53
Bio & Compensation  - Reuters
Alan F. Joslyn Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters